Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clini...
Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strateg...
Moderna, Inc. (NASDAQ:MRNA) shares initially surged Thursday, but have since retreated after the company announced the publication of its Phase 3 study results evaluating mRNA -1010 in the New England Journal of Medicine.
Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 260% year on year to $389 mil...
Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 260% year on year to $389 mi...
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday morning. Here’s what you need to know. Moderna beat analysts’ revenue expec...
Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat
